The Lancet thelancet.com

[Series] New landscape of the diagnosis of Alzheimer's disease

thelancet.com·34w

[Correspondence] World Heart Federation: global ambitions on NCDs

thelancet.com·34w

[Series] Alzheimer's disease outlook: controversies and future directions

thelancet.com·34w

[Editorial] Alzheimer's disease: are health systems ready?

thelancet.com·34w

[Correspondence] Harms of the US travel ban to the physician workforce

thelancet.com·35w

[Comment] Dual incretin agonist for paediatric type 2 diabetes: an eagerly awaited opportunity

thelancet.com·35w

[Review] The future of type 1 diabetes therapy

thelancet.com·35w

[Comment] ATG as disease-modifying therapy for new-onset type 1 diabetes

thelancet.com·35w

[Articles] Minimum effective low dose of antithymocyte globulin in people aged 5–25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multi...

thelancet.com·35w

[Articles] Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVAN...

thelancet.com·35w

[Articles] Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study

thelancet.com·35w

[Comment] Seizure-induced apnoea and the risk of sudden unexpected death in epilepsy

thelancet.com·35w

[Articles] Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, p...

thelancet.com·35w

[Comment] Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy

thelancet.com·35w

[Articles] Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVAN...

thelancet.com·35w

[Comment] Icotrokinra in psoriasis: IL-23 receptor antagonism via oral peptide with biologic-level efficacy

thelancet.com·35w

[Articles] Risk markers for sudden unexpected death in epilepsy: an observational, prospective, multicentre cohort study

thelancet.com·35w

[Comment] Seizure-induced apnoea and the risk of sudden unexpected death in epilepsy

thelancet.com·35w

[Articles] Efficacy and safety of tirzepatide in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, p...

thelancet.com·35w

[Comment] Evaluating how the Trump administration will affect health outcomes

thelancet.com·35w

Log in to enable infinite scrolling